Depression Treatment in General Medical Settings

Status Completed

Clinical Trial Summary

The purpose of this study was to examine the effect of a new disease management model for depression, the Collaborative Depression Management Program (CDMP), designed to improve clinical outcomes and increase depression treatment in general medical settings.

Clinical Trial Description

Clinically depressed individuals that could benefit from newer treatments for depression often do not receive care. Low treatment rates are of particular concern since depression is projected to be the second leading cause of disability worldwide by 2010. Major depression has been the focus of numerous intervention studies with primary care patients during recent years. However, despite advances in the development and testing of quality intervention models for depression treatment, very little is known about the effectiveness of interventions with Latinos. This is important because Latinos are less likely than whites to receive depression treatment, even though the rates of depression are similar for both groups. A major public health challenge is to make available the benefits of intervention developments in depression treatment for all groups in society. As a first step, we examined the impact of a quality depression intervention with Puerto Ricans. The specific aims were:

1. To examine the effect of a Collaborative Depression Management Program in reducing depressive symptoms, improving quality of life, and decreasing health-related functional impairment among Puerto Rican patients in general medical settings.

2. To determine whether a Collaborative Depression Management Program is effective in improving satisfaction with care and reducing barriers to depression treatment among Puerto Rican patients in general medical settings.

This study employed a randomized experimental design. Depressed patients receiving general medical care were assigned to one of two conditions: 80 to the Depression Management Program and 80 to treatment as usual. All subjects completed assessments at baseline, week 8, week 16 and week 24. Our overall programmatic goals were to increase the likelihood that depressed patients receive care and to make available for the Puerto Rican community advances in the treatment of major depression. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00797901
Study type	Interventional
Source	University of Puerto Rico
Contact
Status	Completed
Phase	N/A
Start date	August 2004
Completion date	April 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03062150` - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression	N/A
Completed	`NCT04352101` - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits	Phase 4
Completed	`NCT02855918` - Blood Biomarkers in Suicidal Behaviour	N/A
Recruiting	`NCT03039387` - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients	N/A
Recruiting	`NCT02213016` - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients	Phase 4
Completed	`NCT01636791` - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care	Phase 3
Completed	`NCT01683539` - Understanding How Cognitive Remediation Works	N/A
Recruiting	`NCT02237937` - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene	Phase 4
Completed	`NCT01201148` - Open Pilot Trial of TES for Depression	Phase 2
Completed	`NCT00953108` - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients	Phase 3
Completed	`NCT00806143` - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression	Phase 4
Terminated	`NCT01244711` - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Phase 4
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Terminated	`NCT00695552` - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients	N/A
Completed	`NCT00482482` - Yoga in Unipolar and Bipolar Disorders	N/A
Completed	`NCT00532480` - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine	Phase 4
Completed	`NCT00466323` - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.	N/A
Completed	`NCT00616759` - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol	N/A
Recruiting	`NCT00209807` - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder	Phase 4
Completed	`NCT00167310` - Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.